AlphAIAlphAI — Financial news for AI agents
seekingalpha.com$HIMS

Hims & Hers Health declines following double miss, lowered guidance

Hims & Hers Health (HIMS) fell 2% in after-hours trading after Q3 results missed revenue and earnings estimates. The company lowered 2026 revenue guidance to $3.13B-$3.15B, down from previous forecasts.

Original reporting
seekingalpha.com
Published Nov 9, 2026, 10:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 10:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Hims & Hers Health declines following double miss, lowered guidance — source image
Source · seekingalpha.com
Decision brief

The 30-second read

$HIMSBearishMed
01

Why it matters

The earnings miss and guidance reduction are likely to trigger short‑term selling pressure, though longer‑term catalysts remain uncertain.

02

Market read

The news directly affects HIMS stock and may influence sentiment toward the broader telehealth sector.

03

What to watch

Potential upcoming partnerships or regulatory changes could offset guidance shortfall.

Relevance 7/10Novelty 7/10Timing: after‑hours today

Background

Hims & Hers Health reported Q3 results that missed expectations on both earnings and revenue, and trimmed its full‑year revenue outlook.

Company-level read

Ticker impact

$HIMSBearishMedium confidence
Context

Q3 earnings miss and lowered 2026 revenue guidance to $3.13B-$3.15B.

Expected impact

downward pressure as market prices in the lower guidance

Evidence & confidence

Guidance cut signals slower growth; after‑hours decline already observed.

Market effects

Sector

Telehealth sector may see broader sell‑off as earnings miss highlights demand uncertainty.

Regional

U.S. market participants may adjust exposure to digital health stocks.

Global

Limited; impact confined to U.S. listed telehealth companies.

Counterpoint

What could challenge this read

If the company can accelerate cost efficiencies, the dip may be overblown.

Key entities

  • company
    Hims & Hers Health

    Telehealth provider listed on Nasdaq under ticker HIMS.

Read at source← All news

StoryHims & Hers posts 49% revenue growth but margin collapse and cuts 2026 guidance

Also covered by

4 outlets

Related articles

$HIMSMed

HIMS May See Heightened ‘Gyrations’ As Weight-Loss Drug Trends Fuel Subscriber Uncertainty, Jefferies Warns – Stock Hits 7-Month Lows

Hims & Hers Health (HIMS) shares fell 15% after Q3 earnings missed expectations, with subscribers declining sequentially. Jefferies lowered its price target to $24, citing volatility from weight-loss drug trends. Needham reduced its target to $32 but kept a 'Buy' rating. The company reported a Q3 loss and cut its FY2026 EBITDA and revenue guidance.

finance.yahoo.com
$HIMSHighAI 8/10

Hims & Hers Stock Falls 15% on Weak Q4 Revenue Outlook

Hims & Hers Health (HIMS) shares dropped 15% after the company issued Q4 revenue guidance below expectations, forecasting $875M–$895M vs. analysts' $955.1M estimate. Q3 revenue grew 49% to $890.4M but gross margin declined to 57% from 74%. The company also faces regulatory challenges over weight-loss medications and data privacy.

grafa.com
$HIMSHighAI 8/10

Hims & Hers cuts 2026 earnings outlook despite 49% revenue growth

Hims & Hers Health (HIMS) reported 49% revenue growth in Q3, but lowered its 2026 adjusted EBITDA forecast to $257M-$277M. Revenue guidance was tightened to $3.13B-$3.15B, with Q4 sales expected at $875M-$895M. International revenue surged 321%, while gross margin contracted to 57% from 74%. The company reported a net loss of $33M, with adjusted EBITDA margin falling to 9% from 13%.

finance.yahoo.com